Acrivon AB
559152-0944ActiveDeveloping targeted cancer therapies using proprietary proteomics platform.
Clinical Stage Biotechnology Companyacrivon.com
Yleiskatsaus
- 10–19
- Työntekijät
- 20–50milj SEK
- Liikevaihto
- 2018
- Perustettu
Avainpäättäjät
Peter Blume-Jensen
CEO, President, Founder Chairperson
David Proia
SVP, Biology and Drug Discovery
Eric Devroe
Chief Operating Officer
Ivana Magovčević-Liebisch
Director
+21 lisää yhteystietoja Funnelfeedrissä
Kuvaus
Acrivon Therapeutics is a clinical-stage oncology company focused on developing targeted therapies to improve patient lives. They utilize their proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which moves beyond traditional genomics. This platform generates unique OncoSignature co...
APIM THERAPEUTICS AS